Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
130 studies found for:    INCB018424
Show Display Options
Rank Status Study
1 Terminated
Has Results
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: Ruxolitinib
2 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
3 Not yet recruiting A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Condition: Vitiligo
Interventions: Drug: INCB018424 cream;   Drug: Vehicle cream
4 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
5 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
6 Completed INCB018424 in Patients With Advanced Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Intervention: Drug: INCB018424
7 Completed A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 phosphate cream;   Drug: Dovonex® calcipotriene 0.005%;   Drug: Diprolene® AF betamethasone dipropionate 0.05% cream.;   Drug: Placebo cream
8 Completed
Has Results
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib
9 Recruiting A Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: INCB018424 cream;   Drug: Triamcinolone 0.1% cream;   Drug: Vehicle cream
10 Completed
Has Results
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
11 Active, not recruiting A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
Condition: Alopecia Areata
Interventions: Drug: Placebo Cream;   Drug: INCB018424 Phosphate Cream
12 Completed A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 Phosphate Cream;   Drug: Placebo Cream
13 Completed
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
14 Completed Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Condition: Plaque Psoriasis
Intervention: Drug: INCB018424
15 Terminated
Has Results
Ruxolitinib in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
16 Active, not recruiting Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Intervention: Drug: Ruxolitinib
17 Completed
Has Results
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: INCB018424;   Drug: Placebo
18 Recruiting Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic;   Other Diseases of Blood and Blood-Forming Organs;   Chronic Lymphocytic Leukemia
Intervention: Drug: Ruxolitinib
19 Recruiting Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Drug: TKI
20 Active, not recruiting Study of Ruxolitinib for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaires

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.